CA2360046A1 - Lymphocytes gamma delta actives in vitro - Google Patents
Lymphocytes gamma delta actives in vitro Download PDFInfo
- Publication number
- CA2360046A1 CA2360046A1 CA002360046A CA2360046A CA2360046A1 CA 2360046 A1 CA2360046 A1 CA 2360046A1 CA 002360046 A CA002360046 A CA 002360046A CA 2360046 A CA2360046 A CA 2360046A CA 2360046 A1 CA2360046 A1 CA 2360046A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- delta
- gamma
- leukemia
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000338 in vitro Methods 0.000 title abstract description 8
- 210000004698 lymphocyte Anatomy 0.000 title description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 121
- 210000004027 cell Anatomy 0.000 claims abstract description 55
- 208000032839 leukemia Diseases 0.000 claims abstract description 38
- 230000004913 activation Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000003306 harvesting Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 abstract description 23
- 239000000427 antigen Substances 0.000 abstract description 13
- 108091007433 antigens Proteins 0.000 abstract description 13
- 102000036639 antigens Human genes 0.000 abstract description 13
- 210000005087 mononuclear cell Anatomy 0.000 abstract description 13
- 230000000735 allogeneic effect Effects 0.000 abstract description 11
- 230000001461 cytolytic effect Effects 0.000 abstract description 7
- 230000001472 cytotoxic effect Effects 0.000 abstract description 7
- 108091008874 T cell receptors Proteins 0.000 abstract description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract description 6
- 231100000433 cytotoxic Toxicity 0.000 abstract description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract description 5
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 abstract description 5
- 230000003013 cytotoxicity Effects 0.000 abstract description 5
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 abstract description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 abstract description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 abstract description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract description 3
- 208000004736 B-Cell Leukemia Diseases 0.000 abstract description 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 abstract description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000003747 lymphoid leukemia Diseases 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 27
- 208000024908 graft versus host disease Diseases 0.000 description 27
- 230000000694 effects Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000000719 anti-leukaemic effect Effects 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 102100036008 CD48 antigen Human genes 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010060872 Transplant failure Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HKAANVVRQIPXER-UHFFFAOYSA-M 3-octadecyl-2-[5-(3-octadecyl-1,3-benzoxazol-3-ium-2-yl)penta-2,4-dienylidene]-1,3-benzoxazole;iodide Chemical compound [I-].O1C2=CC=CC=C2[N+](CCCCCCCCCCCCCCCCCC)=C1/C=C/C=C/C=C1/N(CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2O1 HKAANVVRQIPXER-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- -1 CDB Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000029036 donor selection Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 108010048090 soybean lectin Proteins 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Les patients développant un nombre accru de lymphocytes T .gamma..delta.+ cytotoxiques 2 à 6 mois après une greffe allogène de moelles osseuse sont moins susceptibles de rechute que les autres. Les lymphocytes T .gamma..delta.+ isolés dans le sang de patient présentant plus de lymphocytes T .gamma..delta.+ sont les CD3+CD4-CD8-CD57+, qui sont cytolytiques pour les cellules K562 et expriment le phénotype récepteur V.delta.1 des lymphocytes T. Des lymphocytes T .gamma..delta.+ peuvent être obtenus in vitro par culture de cellules mononucléaires donneuses qui sont enrichies en lymphocytes T .gamma..delta.+ par déplétion immunomagnétique de CD4+ et CD8+ appauvris. Cette préparation cellulaire enrichie en .gamma..delta. a été cultivée sur une combinaison d'anticorps monoclonaux pan-.delta. immobilisés et de lymphocytes B leucémiques récepteurs irradiés. Après quatre semaines, les cultures étaient presque exclusivement des lymphocytes V.delta.1+CD3+CD4-CD8- qui exprimaient les antigènes CD69, CD25 and HLA-DR associés à l'activation. En outre, ils étaient cytolytiques par rapport à la leucémie primaire obtenue à partir des lignées cellulaires leucémiques réceptrices et lymphoblastes, tout en présentant une cytotoxicité minimale contre les cellules mononucléaires normales dérivées des donneuses ou contre les lignées de cellules leucémiques myéloïdes. Ces observations donnent à penser que les lymphocytes T .gamma..delta.+ cytotoxiques sont susceptibles de production in vitro et peuvent présenter un potentiel thérapeutique pour la prévention de la rechute.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11771899P | 1999-01-28 | 1999-01-28 | |
| US60/117,718 | 1999-01-28 | ||
| PCT/US2000/001867 WO2000044893A1 (fr) | 1999-01-28 | 2000-01-27 | Lymphocytes gamma delta actives in vitro |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2360046A1 true CA2360046A1 (fr) | 2000-08-03 |
Family
ID=22374454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002360046A Abandoned CA2360046A1 (fr) | 1999-01-28 | 2000-01-27 | Lymphocytes gamma delta actives in vitro |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1147186A4 (fr) |
| JP (1) | JP2002535002A (fr) |
| AU (1) | AU771710B2 (fr) |
| CA (1) | CA2360046A1 (fr) |
| IL (1) | IL144339A0 (fr) |
| WO (1) | WO2000044893A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1188825A1 (fr) * | 2000-09-18 | 2002-03-20 | Universiteit Leiden | Tranfert d' un récepteur de cellule T dans une cellule effectrice candidate ou son précurseur |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| CN103635573B (zh) | 2011-05-19 | 2016-05-11 | 分子医学研究所 | 包含γδT细胞的淋巴细胞系、其组合物及生产方法 |
| AU2014339926B2 (en) * | 2013-10-25 | 2018-02-08 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta T cells for immunotherapy |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| CA2954546A1 (fr) * | 2014-07-09 | 2016-01-14 | Tc Biopharm Ltd | Lymphocytes t gamma delta et leurs utilisations |
| JP2016077185A (ja) * | 2014-10-14 | 2016-05-16 | 学校法人 聖マリアンナ医科大学 | γδＴ細胞の製造方法および医薬 |
| AU2016312610B2 (en) * | 2015-08-25 | 2023-02-16 | The Uab Research Foundation | Methods for stem cell transplantation |
| EP3853351A1 (fr) * | 2018-09-19 | 2021-07-28 | FUJIFILM Cellular Dynamics, Inc. | Protéine l pour l'activation et l'expansion de cellules immunitaires modifiées par un récepteur d'antigène chimère |
| CN111647070B (zh) * | 2020-06-17 | 2022-06-03 | 深圳豪石生物科技有限公司 | T细胞受体或其抗原结合片段及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639653A (en) * | 1993-07-19 | 1997-06-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy | Method for proliferating Vγ2Vδ2 T cells |
| EP0786664A1 (fr) * | 1996-01-26 | 1997-07-30 | Immunotech | Diagnostic d'infections opportunistes chez les patients atteint du SIDA |
| WO1998033891A1 (fr) * | 1997-01-31 | 1998-08-06 | Hemosol Inc. | Procede pour produire des lymphocytes selectionnes |
| AU746531B2 (en) * | 1998-03-12 | 2002-05-02 | Emory University | Methods and compositions for the selective expansion of gamma/delta T-cells |
-
2000
- 2000-01-27 EP EP00913249A patent/EP1147186A4/fr not_active Withdrawn
- 2000-01-27 CA CA002360046A patent/CA2360046A1/fr not_active Abandoned
- 2000-01-27 IL IL14433900A patent/IL144339A0/xx unknown
- 2000-01-27 JP JP2000596135A patent/JP2002535002A/ja active Pending
- 2000-01-27 AU AU34728/00A patent/AU771710B2/en not_active Expired
- 2000-01-27 WO PCT/US2000/001867 patent/WO2000044893A1/fr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002535002A (ja) | 2002-10-22 |
| AU771710B2 (en) | 2004-04-01 |
| IL144339A0 (en) | 2002-05-23 |
| EP1147186A4 (fr) | 2002-05-15 |
| AU3472800A (en) | 2000-08-18 |
| WO2000044893A1 (fr) | 2000-08-03 |
| EP1147186A1 (fr) | 2001-10-24 |
| WO2000044893A9 (fr) | 2001-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bordignon et al. | Cell therapy: achievements and perspectives | |
| Kolb et al. | Graft-versus-leukemia reactions in allogeneic chimeras | |
| US9925220B2 (en) | Method of expanding double negative T cells | |
| Liu et al. | Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+ CD28-T cells. | |
| Foster et al. | Human CD62L–memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion | |
| JP5008810B2 (ja) | 抑制性Ｔ細胞を誘導するためにＴＧＦ−βを用いる移植拒絶反応を防止する方法 | |
| Verneris et al. | Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma | |
| JP6422344B2 (ja) | 同種抗原反応性の制御性ｔ細胞を増大させる方法 | |
| AU2001253400A1 (en) | A method to prevent graft rejection using TGF-beta to induce T suppressor cells | |
| JP2015513403A5 (fr) | ||
| AU771710B2 (en) | In vitro activated gamma delta lymphocytes | |
| CN113454209A (zh) | 通用型双阴性t细胞的制备和治疗用途 | |
| JP4256431B2 (ja) | 移植片−対−宿主疾患を抑制するサイトカイン、細胞およびマイトジェンの使用 | |
| EP1648508A1 (fr) | Methodes et compositions pour augmenter l'efficacite d'anticorps therapeutiques au moyen de cellules nk alloreactives | |
| US7078034B2 (en) | In vitro activated γ δ lymphocytes | |
| JP4435985B2 (ja) | ＴｃＲγδＴ細胞の生産方法 | |
| Wang et al. | Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo | |
| JP2022522231A (ja) | 抗ｂｃｍａ ｃａｒ ｔ細胞の製造 | |
| US20060057122A1 (en) | Functional assessment, specific enrichment and specific depletion of alloreactive human T cells | |
| WO2014207009A2 (fr) | Procédés et trousses pour déterminer si une cellule nk est activée et peut proliférer | |
| AU2002364230B2 (en) | Methods for the induction of professional and cytokine-producing regulatory cells | |
| US6056951A (en) | Method of reducing the chance of attack of cells in a body by the cellular immune system | |
| WO2023205705A2 (fr) | Lymphocytes t allogéniques pour le traitement de malignités hématologiques | |
| AU2007202534B2 (en) | A method to prevent graft rejection using TGF-beta to induce T suppressor cells | |
| Buckland et al. | Prospects for the Induction of Transplant Tolerance Using Dendritic Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |